The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Vepdegestrant, a proteolysis-targeting chimera (PROTAC) estrogen receptor (ER) degrader, plus atirmociclib (ATI) in ER+/HER2- advanced breast cancer (ABC): TACTIVE-K phase 1b/2 results.
 
Melinda Telli
Consulting or Advisory Role - Arvinas; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Foresight Diagnostics; G1 Therapeutics; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; Merck; Natera; Summit Therapeutics
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); BioNTech SE (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Hummingbird (Inst); Merck (Inst); Pfizer (Inst)
Other Relationship - G1 Therapeutics
 
Manuel Ruiz-Borrego
Honoraria - Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Puma Biotechnology; Roche
 
Kan Yonemori
Honoraria - Asterias Biotherapeutics; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; Genmab; Gilead Sciences; Lilly Japan; Merck KGaA; MSD Oncology; Novartis; Ono Pharmaceutical; PDRadiopharma; Pfizer; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; EP biopharma; GlaxoSmithKline; Haihe Pharmaceutical; Henlius; Lilly Japan; MSD; Ono Pharmaceutical; Takeda
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Genmab (Inst); Haihe Pharmaceutical (Inst); Kyowa Hakko Kirrin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Yanxia Zhao
No Relationships to Disclose
 
Komal Jhaveri
Consulting or Advisory Role - Abbvie; Arivinas; AstraZeneca; BeOne Therapeutics; Bicycle Therapeutics; Biotheranostics; BluePrint Medicines; Bridge Bio Oncology and Rayzebio; Bristol-Myers Squibb; ConcertAI; Daiichi Sankyo; Eisai; Genentech; Gilead Sciences; Halda Therapeutics; Lilly; Mersana; natera; Novartis; Olema Pharmaceuticals; Pfizer; Precede Bio; RAYZEBIO; Relay Therapeutics; Sanofi; Scorpion Therapeutics; Seagen; Zymeworks
Research Funding - AstraZeneca (Inst); Blueprint Medicines (Inst); Bridge Bio Oncology Therapeutics; Context Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck; Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); RayzeBio (Inst); Scorpion Therapeutics (Inst); VelosBio/Merck (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; Gilead Sciences; Intellisphere; Jounce Therapeutics; Lilly; Pfizer; Taiho Pharmaceutical
 
Shusen Wang
No Relationships to Disclose
 
Amita Patnaik
Honoraria - Texas Society of Clinical Oncology (TxSCO)
Consulting or Advisory Role - Bayer; Biotheyx; Bristol-Myers Squibb (I); Daiichi Sankyo, Inc.; Genentech/Roche (I); Gilead Sciences; HalioDx; Ionova; Janssen; Loxo; Merck; MERCK (I); Novartis; Pfizer; Pfizer; Quanta Therapeutics; Scorpion Therapeutics; Seagen; Silverback Therapeutics
Speakers' Bureau - Merck; San Antonio Pancreatic Cancer Symposium
Research Funding - 1200 Pharma (Inst); AADi (Inst); Abbvie (Inst); Alpine Immune Sciences (Inst); Ambrx (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arcus Ventures (Inst); Arvinas (Inst); Astellas Pharma (Inst); BioNTech (Inst); BioTheryX (Inst); Bolt Biotherapeutics (Inst); Carrick Therapeutics (Inst); Compugen (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi-Sankyo (Inst); Ensem (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fochon Pharmaceuticals (Inst); Forty Seven (Inst); Genentech (Inst); Gilead Sciences (Inst); IGM Biosciences (Inst); Infinity Pharmaceuticals (Inst); Institut de Recherches Internationales Servier (I.R.I.S) (Inst); Ionova (Inst); Ionova (Inst); Klus Pharma (Inst); KSQ Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo (Inst); Loxo@Lilly (Inst); Merck (Inst); Moderna Therapeutics (Inst); MOMA Therapeutics (Inst); Nektar (Inst); NiKang Therapeutics (Inst); Olema Oncology (Inst); Ottimo (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Pyrotec Therapeutics (Inst); Quanta Therapeutics (Inst); Roche (Inst); Sanofi (Inst); Scorpion Therapeutics (Inst); Seagen (Inst); Seagen (Inst); SERVIER (Inst); Surface Oncology (Inst); Symphogen (Inst); Syndax (Inst); Tesaro (Inst); Upsher-Smith (Inst); Vigeo Therapeutics (Inst); Vividion Therapeutics (Inst)
 
Jean-Sebastien Frenel
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca (Inst); Clovis Oncology (Inst); Daiichi Sankyo Europe GmbH (Inst); Eisai; Exact Sciences (Inst); Gilead Sciences; GlaxoSmithKline; Lilly; MSD Oncology (Inst); Novartis (Inst); Pfizer; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo Europe GmbH; Gilead Sciences; Lilly; MSD Oncology; Novartis; Pfizer; seagen
 
Ping Xu
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Lana Tran
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Shaparak Lonning
Employment - Bluefin Biomedicine (I); Pfizer
Leadership - Bluefin Biomedicine (I)
Stock and Other Ownership Interests - Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Pfizer; Sanofi; Seagen
Patents, Royalties, Other Intellectual Property - Bluefin Biomedicine (I)
 
Noah Berkowitz
Employment - Arvinas
Leadership - Arvinas
Stock and Other Ownership Interests - Arvinas
 
Yuanyuan Zhang
Employment - Arvinas
Stock and Other Ownership Interests - Arvinas
 
Marco Mazzoletti
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Toru Mukohara
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Kyowa Kirin; Lilly Japan; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Eisai; Micin; Pfizer
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Gilead Sciences (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sysmex (Inst)